Brain radiotherapy (BR) is a well-recognized approach for multiple brain metastases (BMs)
from non–small-cell lung cancer (NSCLC). However, the prognosis for these patients …

Background Brain metastases (BMs) develop in 20–65% of non-small cell lung cancer
(NSCLC) patients and are associated with a poor prognosis. Apatinib, a tyrosine kinase …

Background: Brain radiotherapy is the standard treatment option for multiple brain
metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the absence of a …

Objective: Lung cancer is the leading cause of cancer-associated mortality worldwide.
Central nervous system (CNS) metastasis is a prevalent and serious complication. The most …

Background: Existing evidence demonstrates that radiotherapy and antiangiogenic drugs
have synergistic antitumour effects and may be a promising treatment option for patients with …

Background So far, the treatment options for most advanced non-small cell lung cancer
(NSCLC) with brain metastasis have been limited. Apatinib, an oral tyrosine kinase inhibitor …

Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in
China, exerts antiangiogenic and antineoplastic function through selectively binding and …

Background: Symptomatic multiple brain metastases with peritumoral brain edema (PTBE)
occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or …

Background: The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients
with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases …

2021 Background: Veliparib (V) is a potent, orally bioavailable PARP inhibitor that crosses
the blood brain barrier. Phase 2 trials in BRCA pts as monotherapy or in unselected pts in …